Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 versus tiotropium in moderate to severe COPD
2011-000960-93Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Glycopyrronium bromide arm with Tiotropium bromide arm (2 arms). Primary endpoint: Trough forced expiratory volume in 1 second (FEV1). Started Mar 2012; status: completed.
02
Drugs
glycopyrroniumtiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-000960-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000960-93.